3 High-Flying Stocks That Could Soar Even More in 2025
And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...
Verona Pharma’s Ohtuvayre: Strong Performance and Growth Potential Drive Buy Rating
Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...
Verona Pharma price target raised to $60 from $42 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...
Is Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...
2minutemedicine.com6d
Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease
Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...
Investor's Business Daily on MSN9d
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Week
Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.
Verona Pharma stock soars to all-time high of $51.88
In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...
Investing14d
Roth/MKM initiates coverage on Verona Pharma stock with Buy rating and strong upside potential
The bullish stance is based on the potential of Verona Pharma's Ohtuvayre™, which is expected to address a substantial total addressable market (TAM) of approximately 8.6 million symptomatic patients ...